Oral minoxidil VDPHL01 keeps hair gains at 12 months, company says; morphea and systemic sclerosis tied to higher cancer incidence

A handheld dermatoscope standing upright on its ribbed grip, its round lens head facing the viewer.

Veradermics reported company topline 12-month results from its phase 2/3 Study 302 of VDPHL01, an extended-release oral minoxidil, in 519 men with pattern hair loss.

A Quebec cohort study in JAMA Dermatology found higher than expected cancer incidence in patients with morphea and with systemic sclerosis.

  • Research Nov 9, 2026
    Veradermics reported company topline 12-month results from Study 302, a phase 2/3 trial that randomized 519 men with mild-to-moderate pattern hair loss to VDPHL01 8.5 mg once or twice daily or placebo, with placebo patients crossed over to the drug after month 6. Non-vellus hair count rose 43.9 hairs/cm² with twice-daily and 29.7 hairs/cm² with once-daily dosing from baseline to month 12, the company said. Placebo-controlled month-6 results were reported in April, according to Healio. The company reported no treatment-related serious adverse events. VDPHL01 is not FDA approved.
  • Research Nov 11, 2026
    In linked administrative health databases from Quebec, Canada, covering 1996 to 2019, overall cancer incidence was increased in 6,181 patients with morphea (standardized incidence ratio 1.24, 95% CI 1.14 to 1.35) and 8,133 with systemic sclerosis (1.37, 95% CI 1.27 to 1.48), according to the study published Nov. 11 in JAMA Dermatology. Hematologic cancer risk was elevated in systemic sclerosis (standardized incidence ratio 2.40, 95% CI 1.92 to 2.96). Immunosuppressant use was associated with lower cancer risk in both groups.

The weekly innovation roundup for dermatology, published every Sunday for the week before; every item links to its sources. Latest dermatology news · All specialties

Latest news

Tagged dermatology, from the daily briefing

  1. Neoantigen therapy plus pembrolizumab raises 24-month recurrence-free survival to 82.2% from 70.0% in melanoma
  2. Ixekizumab plus tirzepatide beats ixekizumab alone at 52 weeks in psoriatic arthritis with obesity
  3. Phase 2 trial of brepocitinib, an oral TYK2 and JAK1 inhibitor, reports improvement in cutaneous sarcoidosis

See all the latest news